Acadia Pharma (ACAD) Tops Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Acadia Pharma (ACAD) Tops Q3 EPS by 11c

ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results

October 30, 2019 4:05 PM EDT

- 3Q19 Net Sales Grew to $94.6 Million, a 62% Increase Over 3Q18

- 2019 Net Sales Guidance Increased to $330 to $340 Million

- Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30,... More